Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study has found.

But turning this crisis into an opportunity is possible. To mitigate the effects of the funding freeze, Bekker said swift ...

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Nearly half of all new cases in 2022 were in the South. "The frustrating part is we have the tools now to stop it." ...

A study from researchers at Wake Forest University School of Medicine highlights a new approach in addressing conductive hearing loss. A team of scientists, led by Mohammad J. Moghimi, Ph.D., ...

During the opening day of the Conference on Retroviruses and Opportunistic Infections, Rebecca Denison, a decades-long HIV ...

PEPFAR, a global program to combat AIDS, faces an existential threat due to partisan politics, but Congress has an opportunity to reform the program and ensure its continued success.

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

The Conference on Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about ...